CAR T cells armed with IL-15 show promise in treating solid cancers

New advancements in immunotherapy at Texas Children's are giving children and adolescents a fighting chance against cancer. These breakthroughs mean less toxic treatments and more hope for young patients and their families.

The article highlights Drs. Meena Hegde and Shoba Navai, who are developing immunotherapy for solid tumors, and Drs. Nabil Ahmed and Baheyeldin Salem, who are using it to find ways to prevent relapse of the most common type of childhood leukemia – acute lymphoblastic leukemia.

With 250 active trials and over 40 research laboratories, Texas Children’s is at the forefront of precision medicine and cellular immunotherapy. By combining unique in-house and clinical-grade cell manufacturing capabilities with world-leading clinical and translational research, Texas Children’s Cancer and Hematology Center provides access to new therapies through national clinical trials, enabling patients to receive cutting-edge treatment close to home.

Image caption: Texas Children’s is a hub for multi-disciplinary childhood cancer research and home to world-class expertise and facilities for cell and immunotherapies. Drs. Hegde and Navai (top left panel, front row, L-R), Dr. Salem (bottom, second panel from left) and Dr. Ahmed (bottom right panel)

Read the full article and meet clinical researchers right here at Texas Children's who are making a difference.